NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Owlstone Medical

Owlstone Medical

Private
CambridgeHealthcare & Life Scienceshttps://www.owlstonemedical.com/

Last Round

Grant

Oct 6, 2025

Total Funding Raised

$151.85M

Company Overview

Owlstone Medical is a diagnostic equipment company that provides a Breath Biopsy platform for early disease detection and precision medicine.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Drug Discovery, Clinical Trials, Precision Medicine, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales, Government Contracts, Hardware + Subscription

AI Layer

Application

Keywords

Breath Biopsynon-invasive diagnosticsbreath analysisbreath testVOC analysisearly disease detectionbiomarker discoverycancer breath testclinical trial servicesprecision medicinelaboratory servicesion mobility spectrometryFAIMScompanion diagnosticsbreathomicsat-home breath testingliquid biopsy alternativedigestive health diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Owlstone Medical Comparables

Compare Owlstone Medical with similar companies based on industry and business-model similarity.

Owlstone Medical comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Breathomix
77%
Menssana Research Inc.
77%
Breathe BioMedical
77%

Owlstone Medical Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 6, 2025
Corporate FundingMar 25, 2025
Series EJan 15, 2025
Corporate FundingApr 25, 2024
GrantApr 25, 2024
Series D
Sep 7, 2021

Key People

Founding team and executive leadership

Bret Bader

Chief Executive Officer

Executive Team

Neil Tween

Chief Financial Officer

Executive Team

Owlstone Medical Investors

Notable investors and investment history

Owlstone Medical investors
InvestorRounds
Horizons VenturesSeries E, Series D, Series C
Gates Family FoundationSeries E
Aviva VenturesSeries E, Series C, Series A
Gates FoundationSeries E, Corporate Funding
Aviva VenturesSeries A, Series E
Bill & Melinda Gates FoundationGrant, Series E
Cystic Fibrosis FoundationCorporate Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 7, 2025

    POSEIDON program aims for low-cost cancer screening via breath biopsy, funded by ARPA-H grant.

  • Apr 6, 2025

    Added Manchester Worldwide Ltd as a customer

Owlstone Medical Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Owlstone Medical Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Owlstone Medical's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range148
Year Founded2003
Last FundingOct 6, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.